ORNBV Orion Oyj Class B

Orion Research Foundation grants EUR 1,109,000 for research in 2025

Orion Research Foundation grants EUR 1,109,000 for research in 2025

Orion Research Foundation grants EUR 1,109,000 for research in 2025

Press release 22 November, 2024 at 9.00 EET

Orion Research Foundation sr is distributing EUR 1,109,000 in research grants based on applications for 2025. Orion Research Foundation awards grants of max EUR 50,000 for 19 researchers for postdoctoral research and max EUR 6,000 for 93 young researchers for doctoral dissertation work. 

Orion Research Foundation sr is annually distributing its return on investment and donations from Orion Corporation as grants for young researchers for doctoral dissertation work and postdoctoral research. In the last few years the Research Foundation has been distributing annual grants based on applications for the total sum of MEUR 1 for research in medicine, veterinary medicine, pharmacy and related sciences, such as chemistry and physics.

Grants for 2025

Grants for postdoctoral research, EUR 25,000 – 50,000 

Aatsinki Anna-Katariina, LT, Turun yliopisto, Toiminnalliset vatsavaivat ja suolistomikrobiston kehitys lapsuudessa, EUR 25,000

Acosta Manzano Francisco Miguel, Researcher, Turun yliopisto, Medicity (University of Turku) and Turku PET Centre (Turku University Hospital), Unlocking the Power of Brown Fat: New Targets in the Fight Against Cardiometabolic Disease, EUR 50,000

Awad Shady, M.D., Ph.D., University of Oxford, Oxford, UK, Identification of Molecular Vulnerabilities Role in TP53-mutant Leukemic Evolution of Myeloproliferative Neoplasms, EUR 25,000

Carpén Timo Pertti Mikael, LKT, dosentti, erikoislääkäri, palliatiivinen erityispätevyys, Helsingin yliopisto, Virtual symptom screening with Targeted Early Palliative care (STEP2) versus usual care for patients with advanced cancer: a randomized controlled trial., EUR 40,000

Göös Helka Linnea, FT, Suomen Punainen Risti, Veripalvelu, Enhancing CAR-NK cell effectiveness using base editing, EUR 25,000 €

Häkli Martta Ida Emilia, Tekniikan tohtori, Center for iPS Cell Research and Application, Kyoto University, Hypertrofinen kardiomyopatia kantasolupohjaisissa sydänorganoideissa, EUR 30,000

Kim Daehong, Postdoc Fellow, University of Zurich, University of Helsinki, Unravelling gastrointestinal graft-versus-host disease: Organoid transplantation and advanced immune profiling in preclinical models, EUR 25,000 €

Korvenlaita Nea Karoliina, Farmasian tohtori, Johns Hopkins School of Medicine, Department of Molecular & Comparative Pathobiology, Baltimore, USA, Aivosairauksien diagnostiikkaa uusin menetelmin: Solunulkoisista vesikkeleistä parempia biomarkkereita, EUR 50,000

Kositsky Adam, FT, Itä-Suomen yliopisto Kuopion kampus, Piezo1 for Tendon: Understanding Biomechanical and Bioregenerative Effects (PiezTUBBE), EUR 30,000

Koskinen Maija-Kreetta, Filosofian tohtori, Helsingin yliopisto, Sleep well and keep calm: Neural mechanisms of sleep disruption-induced anxiety, EUR 25,000

Laivuori Silja Mirjami, Lääketieteen tohtori, Helsingin yliopisto, Peripheral arterial disease in women., EUR 25,000

Lautaoja-Kivipelto Juulia Helene, Liikuntatieteiden tohtori, Oulun yliopisto, The effects of exercise on adipose tissue mitochondrial function and NAD+ metabolism, EUR 30,000

Muroke Valtteri, LT, Helsingin yliopisto, Helsingin Yliopistollinen Keskussairaala, Inflammation and coronary artery disease - Effects of colchicine on proteomic and metabolomic biomarkers in the COLCOT trial, EUR 40,000

Mäkitaipale Heidi Johanna, ELT, pieneläinsairauksien erikoiseläinlääkäri, Helsingin yliopisto, Kaniinien suun mikrobiomi ja sen yhteys krooniseen hammassairauteen, EUR 30,000

Parvanian Sepideh, PhD, MBA, Åbo Akademi, Cell biology department, Contrasting immunogenic and non-immunogenic bladder tumors: immune microenvironment, metabolic influences, and therapeutic resistance, EUR 25,000

Rajamaki Blair, Researcher, Itä-Suomen yliopisto Kuopion kampus, Temporal changes to comorbidity clusters in people with type 2 diabetes in Finland and Australia, EUR 25,000

Savukoski Susanna Marianne, Lääketieteen tohtori, Oulun yliopisto, Hormonikorvaushoidon pitkäaikaiset terveysvaikutukset ennenaikaisesti vaihdevuosiin tulleilla naisilla, EUR 40,000

Urpa Lea Martta, Researcher, Helsingin yliopisto, Understanding the relationship between disordered sleep and autism symptomatology, EUR 40,000

Yrjölä Pauliina Anna Henriikka, Tekniikan tohtori, sairaalafyysikko, Helsingin yliopisto, Biomarkers of adverse structural-functional development in preterm infants, EUR 30,000

Orion Reaserch Foundation awards grants of max EUR 50,000 for 19 researchers for postdoctoral research. These grants are in total EUR 610,000.

Grants for doctoral dissertation work, EUR 3,000 – 6,000

In addition, Orion Research Foundation has awarded EUR 3,000 – 6,000 for 93 researchers for doctoral dissertation work. These grants are in total EUR 499,000.

Orion Research Foundation sr

More info:

Siiri Lehtinen

Head of Orion Research Foundation

Tel: +358 (0)10 426 4409

siiri.lehtinen(at)orion.fi

Publisher

Orion Research Foundation sr

Attachment



EN
22/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Darolutamide receives EU approval in third indication for patients wit...

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer ORION CORPORATION PRESS RELEASE 21 JULY 2025 at 10:30 EEST           Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).Approval is based on positive results from the pivotal Phase III ARANOTE trial.This broadened indication allows doctors to use darolutamide plus ADT, wi...

 PRESS RELEASE

Euroopan Unionilta hyväksyntä darolutamidin kolmannelle käyttöaiheelle...

Euroopan Unionilta hyväksyntä darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa ORION OYJLEHDISTÖTIEDOTE 21.7.2025 klo 10.30          Euroopan Unionilta hyväksyntä darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa Euroopan komissio on myöntänyt darolutamidille myyntiluvan levinneen hormonisensitiivisen eturauhassyövän (mHSPC) hoitoon yhdessä tavanomaiseen hormonaalisen hoidon (androgeenideprivaatioterapia eli ADT-hoito) kanssa. Päätös perustuu satunnaistetun (vaiheen III) ARANOTE-tutkimuk...

 PRESS RELEASE

Orion Group Half-Year Financial Report January–June 2025

Orion Group Half-Year Financial Report January–June 2025 ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2025 18 JULY 2025 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2025 April–June 2025 Highlights Net sales totalled EUR 416.5 (April–June 2024: 328.2) million Operating profit was EUR 104.6 (65.8) millionBasic earnings per share were EUR 0.59 (0.37)Cash flow from operating activities per share was EUR 0.57 (0.20)Outlook for 2025 was upgraded in July: Net sales are estimated to be EUR 1,630 million to EUR 1,730 million. Operating profit is estimated to be EUR 400 m...

 PRESS RELEASE

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025 ORION OYJ PUOLIVUOSIKATSAUS 1–6/2025 18.7.2025 klo 12:00 Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025 Huhti–kesäkuu 2025 lyhyesti Liikevaihto oli 416,5 miljoonaa euroa (328,2 miljoonaa euroa 4–6/2025)Liikevoitto oli 104,6 (65,8) miljoonaa euroaLaimentamaton osakekohtainen tulos oli 0,59 (0,37) euroaOsakekohtainen liiketoiminnan rahavirta oli 0,57 (0,20) euroaNäkymäarvio vuodelle 2025 päivitettiin heinäkuussa. Liikevaihdon arvioidaan olevan 1 630–1 730 miljoonaa euroa. Liikevoiton arvioidaan olevan 400–500 miljoonaa euroa. Tam...

 PRESS RELEASE

Orion Corporation’s financial reporting and Annual General Meeting in ...

Orion Corporation’s financial reporting and Annual General Meeting in 2026 ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 18 JULY 2025 at 9.30 EEST         Orion Corporation’s financial reporting and Annual General Meeting in 2026 Orion Corporation will publish its Financial Statement Release 2025 on Thursday, 12 February 2026. The publication dates of the Interim Reports and the Half-Year Financial Report in 2026 are as follows: Interim Report January-March 2026 Thursday 23 April 2026 Half-Year Financial Report January-June 2026 Friday 17 July 2026 Interim Report Ja...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch